Huayi Li
Overview
Explore the profile of Huayi Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
551
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wen Y, Xia Y, Yang X, Li H, Gao Q
Trends Immunol
. 2025 Jan;
46(2):153-165.
PMID: 39890548
Tumor-infiltrating regulatory T (TI-Treg) cells constitute key components within the tumor microenvironment (TME) to suppress antitumor immunity and facilitate tumor progression. Although multiple therapies have been developed to eliminate TI-Treg...
2.
Li H, Xu Y, Jiao X, Xu Q, Peng Z, Tang Y, et al.
Med
. 2025 Jan;
100573.
PMID: 39827881
Background: It remains unclear whether adding CTLA-4 blockade to PD-1/PD-L1 blockade improves clinical outcomes in cervical cancer (CC). Methods: In this randomized, double-blind, placebo-controlled, phase 2 study (ClinicalTrials.gov: NCT04590599), patients...
3.
Peng Z, Li H, Gao Y, Sun L, Jiang J, Xia B, et al.
Lancet Oncol
. 2024 Sep;
25(10):1288-1297.
PMID: 39276785
Background: Ovarian clear cell carcinoma rarely responds to second-line chemotherapy, the recommended treatment for relapsed epithelial ovarian cancer. Here, we report the activity and safety of sintilimab in combination with...
4.
Feng J, Wei L, Li H, Shen J
J Colloid Interface Sci
. 2024 Aug;
678(Pt A):176-185.
PMID: 39186897
Synergistic effects among different metals have positioned multimetallic electrocatalysts as promising facilitators for enhancing the oxygen evolution reaction (OER), though understanding their precise mechanisms has remained elusive. Delving into the...
5.
Luo Y, Xia Y, Liu D, Li X, Li H, Liu J, et al.
Cell
. 2024 Jul;
187(18):4905-4925.e24.
PMID: 38971151
Homologous recombination deficiency (HRD) is prevalent in cancer, sensitizing tumor cells to poly (ADP-ribose) polymerase (PARP) inhibition. However, the impact of HRD and related therapies on the tumor microenvironment (TME)...
6.
Li H, Peng Z, Zhu J, Zhao W, Huang Y, An R, et al.
BMC Med
. 2024 May;
22(1):199.
PMID: 38755585
Background: The prospective phase III multi-centre L-MOCA trial (NCT03534453) has demonstrated the encouraging efficacy and manageable safety profile of olaparib maintenance therapy in the Asian (mainly Chinese) patients with platinum-sensitive...
7.
Xu Y, Xiong F, Li H, Zheng H, Jiang J, Li Q, et al.
Int J Gynecol Cancer
. 2024 Apr;
34(9):1461-1465.
PMID: 38658024
Background: Platinum-resistant, recurrent ovarian cancer has an abysmal prognosis with limited treatment options. Poly-(ADP-ribose)-polymerase (PARP), angiogenesis, and immune checkpoint inhibitors might improve the outcomes of platinum-resistant, recurrent ovarian cancer, but...
8.
Xiang M, Li H, Zhan Y, Ma D, Gao Q, Fang Y
Mol Cancer
. 2024 Apr;
23(1):73.
PMID: 38581063
T cells are fundamental components in tumour immunity and cancer immunotherapies, which have made immense strides and revolutionized cancer treatment paradigm. However, recent studies delineate the predicament of T cell...
9.
Feng J, Chu C, Liu J, Wei L, Li H, Shen J
J Colloid Interface Sci
. 2024 Jan;
659:330-338.
PMID: 38176242
Oxygen evolution reaction (OER) is a crucial half-reaction in water splitting, generating hydrogen for sustainable development, but it is often subject to sluggish kinetics. Abundant transition metal-based OER electrocatalysts have...
10.
Yan D, Li G, Yuan Y, Li H, Cao H, Dai Y, et al.
Cancer Gene Ther
. 2023 Dec;
31(3):397-409.
PMID: 38102464
Oncolytic viruses (OVs) are emerging as a potentially useful treatment for malignancies due to the capabilities of direct oncolysis and immune induction. Improving the replication of OVs is an effective...